This is a working overview of cyclic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
They found that the elastic stiffness is identical and strength is only slightly lower than those in pristine graphene. In the same year, researchers from University of California, Berkeley and University of California, Los Angeles probed bi-crystalline graphene with TEM and AFM. They found that the strength of grain boundaries indeed tends to increase with the tilt angle. While the presence of vacancies is not only prevalent in polycrystalline graphene, vacancies can have significant effects on the strength of graphene. The consensus is that the strength decreases along with increasing densities of vacancies. Various studies have shown that for graphene with a sufficiently low density of vacancies, the strength does not vary significantly from that of pristine graphene. On the other hand, a high density of vacancies can severely reduce the strength of graphene. Compared to the fairly well-understood nature of the effect that grain boundary and vacancies have on the mechanical properties of graphene, there is no clear consensus on the general effect that the average grain size has on the strength of polycrystalline graphene. In fact, three notable theoretical or computational studies on this topic have led to three different conclusions. First, in 2012, Kolakowski and Myer studied the mechanical properties of polycrystalline graphene with "realistic atomistic model", using molecular-dynamics (MD) simulation. To emulate the growth mechanism of CVD, they first randomly selected nucleation sites that are at least 5A (arbitrarily chosen) apart from other sites.
== Inherited thrombocytopenia with normal MPV == ATRUS Syndrome Thrombocytopenia 2 (THC2) Congenital amegakaryocytic thrombocytopenia TAR syndrome Familial platelet disorder with predisposition to AML
== Further reading == Donald, Bruce R. (2011). Algorithms in Structural Molecular Biology. Computational Molecular Biology. Cambridge, Mass.: The MIT Press. ISBN 978-0-262-01559-2. OCLC 1200909148. Jin, Wenzhen; Kambara, Ohki; Sasakawa, Hiroaki; Tamura, Atsuo & Takada, Shoji (May 2003). "De Novo Design of Foldable Proteins with Smooth Folding Funnel: Automated Negative Design and Experimental Verification". Structure. 11 (5): 581–590. doi:10.1016/S0969-2126(03)00075-3. PMID 12737823. Pokala, Navin & Handel, Tracy M. (2005). "Energy Functions for Protein Design: Adjustment with Protein–Protein Complex Affinities, Models for the Unfolded State, and Negative Design of Solubility and Specificity". Journal of Molecular Biology. 347 (1): 203–227. doi:10.1016/j.jmb.2004.12.019. PMID 15733929. Sander, Chris; Vriend, Gerrit; Bazan, Fernando; Horovitz, Amnon; Nakamura, Haruki; Ribas, Luis; Finkelstein, Alexei V.; Lockhart, Andrew; Merkl, Rainer; et al. (February 1992). "Protein Design on Computers. Five New Proteins: Shpilka, Grendel, Fingerclasp, Leather and Aida". Proteins: Structure, Function, and Bioinformatics. 12 (2): 105–110. doi:10.1002/prot.340120203. PMID 1603799. S2CID 38986245.
=== Extracellular matrix adhesion and signaling === Integrin alpha-1 (ITGA1), when linked with Integrin beta-1 (ITGB1), forms the α1β1 Integrin receptor. The α1β1 is a transmembrane extracellular matrix (ECM) receptor that mediates cell adhesion and intracellular signaling. By binding collagen and laminin, ITGA1 allows cells to sense and respond to changes in the ECM. These interactions are how ITGA1 regulates cell-matrix adhesion, focal adhesion formation, ECM organization, and downstream pathways controlling cell survival, proliferation, migration, and differentiation. The molecular functions of ITGA1 include collagen binding, collagen-mediated cell-matrix adhesion, protein interactions involved in signaling pathways, and localizations to the cell surface, plasma membrane, focal adhesions, and integrin complexes. These attributes aid in its function as a key mediator of ECM-dependent cellular communication.
Sources: en.wikipedia.org
==== Clean vehicle and clean energy home improvement tax credits eliminated ==== The tax credit for buying a new qualified electric vehicle or fuel cell electric vehicle is no longer available for purchases made after September 30, 2025. The tax credit for buying a used qualified electric vehicle or fuel cell vehicle from a licensed dealer is no longer available for purchases made after September 30, 2025. The tax credit for installing property to either recharge electric vehicles or to store or dispense clean-burning fuel will no longer be available after June 30, 2026. The tax credit for making qualified energy-efficient improvements to one's home will no longer be available for improvements put into service after December 31, 2025. The tax credit for installing solar electric panels, solar water heaters, wind turbines, geothermal heat pumps, fuel cells, or battery storage technology in one's home will no longer be available for improvements made after December 31, 2025.
His explorations on Pichincha included documenting frequent earthquakes, which led to local rumors attributing the tremors to his presence. Humboldt’s work during this period advanced scientific understanding of high-altitude geology and volcanology.
Within the mesh scaffolding of bat wing skin, collagen fibers cross bones perpendicular to the long axes of the bones, therefore mechanical properties of bat wing skin oriented perpendicular to the long axes of the bones exhibit a lower stiffness than the skin that is oriented parallel to the long axes of the bodies. Stiffer skin is necessary for bat wing skin oriented in the direction parallel to the long axes of the bones to prevent too much deformation of bat wing skin during flight (with respect to the bone), resulting in the shearing of the bat wing skin off of the bone. Flexible skin is necessary for the direction perpendicular to the long axes of the bones for facilitating the shape changes needed for movement and control during flight. This anisotropy of bat wing skin is also useful as method of storing and releasing elastic energy, particularly during the downstroke. During the downstroke, the bat extends its wing and the wing skin experiences an aerodynamic force. The wing skin expands and counteracts the aerodynamic force. After the wing is fully extended, the orientation of the wing is nearly vertical and the aerodynamic forces on the wing are reduced. As the aerodynamic force is reduced, the wing recoils, drawing the digits of the wings together in preparation for the upstroke.
Sources: en.wikipedia.org
Injury is physiological damage to an organism. The response to injury, whether in humans, in other animals, in plants, in fungi, or in single-celled eukaryotes such as choanoflagellates, is substantially shared, implying that the mechanisms are ancient. Injuries can be caused in many ways, including mechanical trauma, toxins, interactions with other organisms, or abiotic factors in the environment. In many animal taxa, injury prompts an inflammatory response that initiates wound healing. In both plants and animals, substances are released to help occlude the wound, limiting fluid loss and the entry of pathogens. Many organisms secrete antimicrobial chemicals, which limit wound infection; animals have immune responses for the same purpose. Both plants and animals have mechanisms of regrowth that may result in complete or partial healing of the injury.
Striking deep into cities like Kyiv, Odessa, and Zaporizhzhia, self-targeting AI drones have misidentified or collided with civilian infrastructure—including business centers, energy grids, and medical centers—resulting in widespread non-combatant fatalities far from the active lines of contact.
On 15 January 2022, the murder of Ebrahim Buzhu took place in Chiclana de la Frontera, Spain. Buzhu, a Dutch drug trafficker of Moroccan origin, was shot through the head and his body was found by a passerby who had notified the Civil Guard. The rented vehicle of Ebrahim Buzhu, next to the body, had been lit on fire. Following an investigation, the Spanish police concluded that Buzhu had been kidnapped and severely tortured, prior to being murdered.
There is no evidence it is more effective than other therapies or sham, or as an adjunct to other treatments, for acute low back pain "Back school" is an intervention that consists of both education and physical exercises. There is no strong evidence supporting the use of back school for treating acute, subacute, or chronic non-specific back pain. Insoles appear to be an ineffective treatment intervention. While traction for back pain is often used in combination with other approaches, there appears to be little or no impact on pain intensity, functional status, global improvement or return to work.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.